DESCRIPTION: (Adapted from the Investigator's Abstract) The proposed research
project seeks to further develop an existing Western blot assay that can detect
the cyclin D1 protein in blood samples and to validate cyclin D1 in blood as a
biomarker for the presence of breast cancer. The validation of bloodborne tumor
derived proteins, such as cyclin D1, as biomarkers that are predictive for the
presence of breast cancer, would allow us to develop new strategies for the
detection, management and follow up of breast cancer. In the U.S., the
incidence of breast cancer has been rising steadily, with over 182,0000 new
cases in 1996; it now affects 1 in 9 women during the course of their lifetime.
Early detection through mammography has been shown to reduce mortality due to
breast cancer, but new technologies that can be used in conjunction with
mammography are needed. Additionally approaches that can provide presurgical
information on likely receptor status or prognosis would greatly aid in making
treatment choices. Lastly, the use of tumor derived proteins as biomarkers may
be useful in patient follow up to predict recurrence or metastases.
Cycylin D1 is an oncoprotein overexpressed in 50-60% of breast tumors, and its
overexpression is strongly associated with estrogen receptor positive tumors
and with a better prognosis. We have developed a Western blot assay that can
detect cyclin D1 in blood plasma samples. Our preliminary studies show that
this protein can be detected in 60% o breast cancer patients and its presence
is strongly associated with breast cancer status. A three year study is
proposed to further refine this assay, complete the necessary laboratory
validation steps and to validate cyclin D1 as a predictive biomarker in an
ongoing molecular epidemiologic case-control study of breast cancer. Cyclin D1
will be analyzed in stored blood plasma samples from 100 cases, 100 benign
breast disease controls, and 100 healthy controls; the association between
cyclin D1 levels and case-control status will be assessed. Additionally, to
investigate the correlation between tissue overexpression of cyclin D1 and the
presence of the protein in blood, stored tissue sections from cases and BBD
controls will be assays for cyclin D1. Lastly the relationship between the
presence of cyclin D1 protein in blood and estrogen receptor status and other
tumor characteristics such as size and stage will be evaluated. This
transitional study will take the necessary steps in validating blood levels of
cyclin D1 as a marker for the presence of breast cancer. Once validated, this
biomarker could be useful in the early detection, management and follow up of
If you are accessing this page during weekend or evening hours, the database may currently be offline for maintenance and should operational within a few hours. Otherwise, we have been notified of this error and will be addressing it immediately.
Please contact us
if this error persists.
We apologize for the inconvenience.
- The DCCPS Team.